FOXO4-DRI: What the Research Actually Shows in 2026

Table of Contents
- Quick Answer
- Is FOXO4-DRI on ClinicalTrials.gov?
- What FOXO4-DRI Is
- Mechanism: How FOXO4-DRI Is Supposed to Work
- Preclinical Evidence: One Keystone Paper Plus a Handful of Replications
- Clinical Evidence in Humans: Zero Published Trials
- Dosing: Research Only, All Extrapolation
- Reconstitution and Handling
- Safety: Animal Data Does Not Equal Human Data
- Drug Interactions
- Regulatory Status (2026)
- The Honest Bottom Line
- Frequently asked questions
- Read Next
- Cycle Lengths
- Lab Monitoring
- Storage & Travel
Quick Answer
FOXO4-DRI is a synthetic D-retro-inverso peptide designed to selectively kill senescent (“zombie”) cells by disrupting the FOXO4-p53 binding interaction inside the cell. The keystone evidence is a single 2017 mouse paper in Cell (Baar et al., PMID 28340339), extended by a handful of independent in vitro and in vivo replications in specific tissues.
There are zero published human clinical trials of FOXO4-DRI as of June 2026. No Phase 0, no Phase 1, no Phase 2. No FDA, EMA, or PMDA approval. No active publicly disclosed IND. The widely circulated Darren Moore self-experimentation (2017-2018) is community anecdote, not evidence. The inventor of the molecule, Dr. Peter de Keizer, has publicly discouraged human self-experimentation and has stated that mouse data does not translate to humans.
The selectivity claim that FOXO4-DRI kills senescent cells “10 times more readily” than healthy cells comes from de Keizer’s public commentary, not from peer-reviewed dose-response data, and the 10:1 ratio is well short of the magic-bullet profile that downstream marketing implies. Of every peptide covered on this site, FOXO4-DRI has the widest gap between consumer hype and published human evidence. This guide is written from that premise.
FOXO4-DRI is sold in the United States exclusively as a research chemical for in vitro use, not for human consumption. Nothing in this guide is medical advice.
Is FOXO4-DRI on ClinicalTrials.gov?
No. As of 2026, there are no FOXO4-DRI human clinical trials registered on ClinicalTrials.gov, and none have been published. Every result cited for FOXO4-DRI comes from cell-culture experiments and mouse studies, not from people. The compound that made headlines is the original peptide from the 2017 Erasmus MC research; the company commercializing that science, Cleara Biotech, has since moved its clinical program to two optimized next-generation candidates rather than the original FOXO4-DRI peptide. So anyone searching ClinicalTrials.gov for “FOXO4-DRI” today will find nothing registered under that name.
What FOXO4-DRI Is
FOXO4-DRI is the D-retro-inverso (DRI) isomer of a short peptide stretch derived from the FOXO4 transcription factor’s binding domain, fused at its C-terminus to a poly-arginine cell-penetrating tag.
“D-retro-inverso” means two things were done together to the original L-amino acid sequence:
- Every L-amino acid was replaced with its D-enantiomer mirror image.
- The sequence was reversed end-to-end.
Performed together, those two operations approximately preserve the side-chain topology of the original L-peptide while making the backbone largely invisible to mammalian proteases. That is the structural trick that gives DRI peptides their relative enzymatic stability in serum and in tissue.
Basic chemistry
- Other names: FOXO4-D-retro-inverso peptide, FOXO4-p53 disruptor peptide, Proxofim (Cleara Biotech’s development name), FOXO4-DRI-1.
- CAS number: 2460055-10-9 (free base). Also indexed as MFCD22566252.
- Molecular formula: C228H388N86O64.
- Molecular weight: approximately 5358 Da (~5.4 kDa). For context, that is roughly the size of insulin (~5.8 kDa) and substantially larger than typical bioregulator peptides such as Epitalon (390 Da) or Semax (~813 Da). The molecular weight matters for dosing arithmetic, because a 1 mg dose of FOXO4-DRI corresponds to only ~0.187 µmol of compound.
- Sequence:
H-ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg-OH. Lowercase letters indicate D-amino acids by convention; the C-terminal arginine-rich stretch (rrkkrgand the upstreamrrrqrrk) is the TAT-like cell-penetrating cargo segment.
Identity at a glance
| Attribute | Value |
|---|---|
| Primary name | FOXO4-DRI |
| Alternate names | FOXO4-D-retro-inverso peptide, FOXO4-p53 disruptor peptide, Proxofim (Cleara Biotech development name), FOXO4-DRI-1 |
| CAS number | 2460055-10-9 (free base); MDL MFCD22566252 |
| Molecular formula | C228H388N86O64 |
| Molecular weight | ~5358 Da (~5.4 kDa) |
| Sequence | H-ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg-OH (D-amino acids) |
| Structural class | Synthetic D-retro-inverso peptide with C-terminal poly-arginine cell-penetrating tag |
| Classification | Investigational senolytic peptide; research chemical (not FDA-approved) |
| Endogenous counterpart | None – designed in silico |
| Origin lab | de Keizer laboratory, Erasmus University Medical Center / UMC Utrecht |
FOXO4-DRI is not a naturally occurring peptide. It has no endogenous human counterpart. It was designed in silico and synthesized by the de Keizer laboratory at Erasmus University Medical Center and UMC Utrecht as the experimental tool that produced the 2017 Cell paper.
Mechanism: How FOXO4-DRI Is Supposed to Work
The mechanism FOXO4-DRI is designed to exploit involves four steps, all of which are established in cell culture and (for the in vivo step) in mice.
1. Senescent cells accumulate with age and after toxic stress. Cellular senescence is a permanent cell-cycle arrest state. Cells enter it after telomere shortening, persistent DNA damage, oncogene activation, or chemotherapy. Senescent cells resist normal apoptosis and secrete a pro-inflammatory mix of cytokines, chemokines, and matrix-remodeling enzymes called the senescence-associated secretory phenotype (SASP). The SASP degrades local tissue function and can propagate the senescent phenotype to neighboring cells.
2. In senescent cells, p53 is sequestered by FOXO4 in nuclear foci. Baar et al. (2017) showed that the forkhead transcription factor FOXO4 binds p53, specifically at the TAD2 transactivation domain, and holds it in nuclear bodies. That sequestration prevents p53 from triggering its normal apoptotic program. The senescent cell stays alive: chronically dysfunctional, secreting SASP, but alive.
3. FOXO4-DRI competitively disrupts the FOXO4-p53 interaction. The DRI peptide enters cells through the poly-arginine cell-penetrating tail (which can cross membranes through several mechanisms, including direct translocation and endocytic uptake), then binds the same p53 TAD2 surface that FOXO4 occupies. FOXO4 is displaced. The freed p53 re-localizes from the nucleus to the cytoplasm and mitochondria and drives intrinsic (mitochondrial) apoptosis in cells that depend on FOXO4-mediated p53 sequestration for survival, i.e., senescent cells.
4. Non-senescent cells are largely spared. Healthy cells do not depend on FOXO4 for p53 management; their baseline p53 is regulated by MDM2 and other inputs. Selectivity in this design comes from the senescent cell’s dependence on the FOXO4-p53 interaction for survival, not from selective cell entry. The CPP tail enters most cell types.
The selectivity caveat that vendor marketing leaves out
Peter de Keizer, the molecule’s inventor, has publicly estimated FOXO4-DRI’s senescent-versus-healthy selectivity at roughly 10:1, not 100:1 or 1000:1. He has stated that next-generation Cleara Biotech candidates aim for 100:1. A 10:1 selectivity ratio is meaningful in cell culture but is not the magic-bullet profile that the popular framing suggests. The 10:1 figure also comes from de Keizer’s commentary in interviews and conference talks, not from a peer-reviewed dose-response study with a stated confidence interval. Take it as a useful order-of-magnitude estimate from the inventor, not as a published parameter.
What the mechanism does not establish
A clear mechanism in cell culture is not the same thing as a clear human outcome. The mechanism narrative does not establish:
- That selective senescent-cell clearance in a healthy adult human produces net benefit. The “good cell vs. bad cell” balance of senescent cells in vivo is more nuanced than the “zombie cell” metaphor implies. Senescent cells contribute to wound healing, tumor suppression, embryonic patterning, tissue remodeling, and placental development. Systemic senolytic exposure in an adult is biologically novel and the long-term cost of repeated clearance is unknown.
- That the cells targeted in the mouse studies are the same populations that would be targeted (or spared) in humans at biohacker dose ranges.
- That the ~10:1 cell-culture selectivity holds in vivo at the doses biohackers actually use.
Preclinical Evidence: One Keystone Paper Plus a Handful of Replications
The honest summary: FOXO4-DRI has a small, technically rigorous, mostly single-lab preclinical literature in animals, plus a handful of independent in vitro and single-tissue replications. There is no published large-animal data (no dog, pig, or non-human primate). There is no published mouse lifespan study despite FOXO4-DRI being the most-hyped senolytic peptide in the consumer space.
The keystone paper (Baar et al., 2017)
The paper that started everything is:
Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, Stryeck S, Rijksen Y, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, van Cappellen WA, van IJcken WF, Houtsmuller AB, Pothof J, de Bruin RWF, Madl T, Hoeijmakers JHJ, Campisi J, de Keizer PLJ. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell 2017 Mar 23;169(1):132-147.e16. PMID: 28340339. DOI: 10.1016/j.cell.2017.02.031.
That paper reported three core in vivo findings in mice:
- Doxorubicin chemotoxicity model. FOXO4-DRI given after doxorubicin reduced doxorubicin-induced senescence in vivo, prevented chemotherapy-associated body weight loss, and normalized liver injury markers.
- Fast-aging Xpd^TTD/TTD mice (a model of accelerated aging caused by a DNA repair defect). FOXO4-DRI dosed over weeks restored fur density, increased running activity, and reduced markers of frailty.
- Naturally aged ~24-month-old mice. FOXO4-DRI restored renal filtration capacity (improved BUN, normalized glomerular markers) and improved physical fitness.
The dosing in that work was 5 mg/kg intraperitoneally every other day for three doses per cycle, with cycles repeated at intervals of two weeks or longer. Hematological toxicity panels reportedly showed no red-flag bone-marrow effects in the mice studied.
That is a single paper. It is real, careful work in mice. It is not a body of human evidence.
Preclinical evidence inventory
The full body of preclinical FOXO4-DRI work, at a glance. Every entry below is an animal or cell-culture study; none of these are human trials.
| Study (PMID) | Model | Dose / Route | Outcome |
|---|---|---|---|
| Baar et al. 2017 (PMID 28340339) – keystone Cell paper | Mice: doxorubicin chemotoxicity, fast-aging Xpd^TTD/TTD, naturally aged ~24-month-old | 5 mg/kg IP, every other day × 3 doses per cycle | Reduced doxorubicin-induced senescence; restored fur density, running activity, renal filtration; “well tolerated” in mice |
| Zhang et al. 2020 (PMID 31959736) | Aged mice – Leydig cells in vivo | Cycled IP dosing | Reduced senescent Leydig cell burden; partial restoration of testosterone (modest effect size). First major independent in vivo replication. |
| Huang et al. 2021 (PMID 33996787) | In vitro expanded human chondrocytes | In vitro exposure | Selectively cleared senescent chondrocytes and reduced SASP markers – but pre-treatment did NOT improve subsequent cartilage formation (negative downstream-function finding) |
| Li et al. 2024 (PMID 39025385) | Aged mice – spermatogenesis | Cycled dosing | Improved spermatogenesis via reduced Leydig-cell SASP. Extension of the Zhang 2020 line. |
| Communications Biology 2025 (PMID 39994346) | Keloid fibroblasts in vitro / organ culture | In vitro exposure | Induced apoptosis in senescent keloid fibroblasts via nuclear exclusion of p53-Ser15 phosphorylation |
| Frontiers in Bioeng 2025 (PMID 41625068) | Human endothelial cells in vitro | In vitro exposure | Activated p53/BCL-2/Caspase-3 axis in senescent endothelial cells; suggests vascular-aging application |
| Naunyn-Schmiedeberg 2026 (review, DOI 10.1007/s00210-026-05309-6) | Review article – CNS senolytic case | N/A – no new primary data | Consolidates brain-aging rationale; explicitly notes no human trials as of 2026, all extrapolated dosing remains theoretical |
Independent and follow-on replications
The body of independent FOXO4-DRI work is small but has grown since 2017. Each study is single-tissue, most are in vitro or single-lab in vivo, and none is in large animals or humans.
Senescent Leydig cell clearance and testosterone restoration in aged mice. Zhang C, Xie Y, Chen H, Lv L, Yao J, Zhang M, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY) 2020 Jan 28;12(2):1272-1284. PMID: 31959736. PMC7053614. This is the first major independent in vivo replication. The effect size was modest but the direction was consistent with the keystone paper.
Senolytic activity on expanded human chondrocytes in vitro. Huang Y, He Y, Makarcyzk MJ, Lin H. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Frontiers in Bioengineering and Biotechnology 2021 Apr 29;9:677576. PMID: 33996787. PMC8116695. An important and underdiscussed finding from this paper: pre-treating expanded chondrocytes with FOXO4-DRI did NOT improve subsequent cartilage formation. It reduced SASP markers, but the downstream functional benefit (the thing patients would actually care about) did not follow. This is a useful “mechanism works but downstream functional benefit is harder to demonstrate” data point that vendor copy never mentions.
Spermatogenesis in aged mice. Li Y et al. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Experimental Gerontology 2024 Oct 1;195:112522. PMID: 39025385. DOI: 10.1016/j.exger.2024.112522. An extension of the Leydig-cell line of work.
Keloid fibroblast apoptosis. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications Biology 2025;8. PMID: 39994346. DOI: 10.1038/s42003-025-07738-0. In vitro and organ-culture evidence that the mechanism extends to dermatologic disease, specifically keloid scarring.
Endothelial cell senescence. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in Bioengineering and Biotechnology 2025;13:1729166. PMID: 41625068. PMC12852416. Activates the p53/BCL-2/Caspase-3 axis in senescent endothelial cells, suggesting potential vascular-aging applications. Still in vitro.
2026 brain-aging review. Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. Naunyn-Schmiedeberg’s Archives of Pharmacology 2026. DOI: 10.1007/s00210-026-05309-6. A review article (not new primary data) consolidating the case for central-nervous-system senolytic application. Notable for stating explicitly that “no human trials [were] conducted as of 2026, [so] any extrapolated dosing remains entirely theoretical.”
What the preclinical literature does not show
- No large animal safety or pharmacokinetic studies have been published. That kind of work would normally close the gap to an IND submission; for FOXO4-DRI, that work is presumably happening inside Cleara Biotech and is not in the public literature.
- No mouse lifespan study. The 2017 Cell paper measured function and tissue markers; it did not show extension of median or maximum mouse lifespan. Other senolytics, including the small-molecule combination dasatinib + quercetin, fisetin, and navitoclax (ABT-263), do have published mouse lifespan studies. The absence of a lifespan study for FOXO4-DRI specifically is notable, given how central life-extension framing is to consumer marketing.
- No published head-to-head comparison with other senolytics.
Clinical Evidence in Humans: Zero Published Trials
Zero published human clinical trials of FOXO4-DRI exist as of June 2026. This is the single most important fact in this guide.
- ClinicalTrials.gov search: No active, completed, or terminated trials of FOXO4-DRI, Proxofim, or any disclosed Cleara Biotech FOXO4-DRI derivative are registered as of the verification date.
- Cleara Biotech (Utrecht, Netherlands; founded 2018 by Peter de Keizer to commercialize FOXO4-DRI–derived senolytics) was, as of its most recent public update (late 2022, via Fight Aging!), optimizing next-generation peptide candidates and “gearing up for clinical development.” No Phase 0 or Phase 1 IND-enabling publication has surfaced in the public scientific literature since.
- No FDA, EMA, or PMDA approval. No orphan designation. No publicly disclosed active IND.
Human evidence inventory
For a senolytic peptide that has been the subject of magazine features, podcast episodes, and a vendor cottage industry since 2017, the published human evidence base is conspicuously thin. The table below catalogs every category of “human evidence” that exists for FOXO4-DRI and grades each by what it can actually establish.
| Source | Type | Evidence grade |
|---|---|---|
| Published Phase 1/2/3 clinical trials | Controlled human trial | None exist. Zero published trials as of June 2026. |
| ClinicalTrials.gov registered studies | Registered protocol | None. No active, completed, or terminated FOXO4-DRI / Proxofim trial registered. |
| Published human pharmacokinetic data | Dose-exposure study | None. No human PK profile, no bioavailability data, no half-life data. |
| Published human case reports | Peer-reviewed observation | None found in PubMed / Google Scholar / case-report literature (benefit or harm). |
| Cleara Biotech IND filings | Regulatory dossier | No publicly disclosed IND for FOXO4-DRI or successor molecules as of mid-2026. |
| Darren Moore self-experimentation (2017-2018) | Single-person anecdote | Not evidence. Confounded by concurrent supplements; no third-party HPLC/MS verification of injected material; biomarker noise within test-retest range; inventor (de Keizer) publicly discouraged. |
| Inventor commentary (Peter de Keizer interviews) | Expert opinion / commentary | Not clinical evidence. Source of the often-cited ~10:1 selectivity figure, but from interviews and conference talks, not peer-reviewed dose-response data. de Keizer himself has stated mouse data does not translate to humans. |
| Vendor / clinic marketing claims of human safety | Commercial claim | Not evidence. Extrapolation from mouse data and anecdotes dressed in the prestige of the Cell journal name. |
| Community forum adverse-event reports | Unstructured anecdote | Not formally published. Injection-site reactions, flu-like syndromes, GI symptoms reported; absence of published case reports likely reflects small denominator + no pharmacovigilance, not safety. |
What fills the human-data vacuum (and why it is not evidence)
Two things fill the absence of human clinical trials. Neither functions as evidence of safety or efficacy.
1. Anecdotal self-experimentation, most prominently Darren Moore. Moore, a 51-year-old American self-experimenter, reported three self-administered FOXO4-DRI cycles between April 2017 and February 2018, documented on the LongeCity and Age-Reversal forums. He claimed subjective endurance increase on treadmill testing, some head-hair regrowth, modest movement in epigenetic-age and telomere-length panels, and a reported few-year drop in “biological age.”
There are several reasons the Moore self-experiment is not evidence:
- He was simultaneously taking multiple other supplements, which destroys the ability to attribute any change to FOXO4-DRI specifically.
- He did not publish or provide independent third-party analytical verification (HPLC plus mass spectrometry on the actual injected material) confirming that what he was injecting was the intended molecule rather than a degradation product, a truncated peptide, or something else entirely.
- Telomere length and epigenetic age assays have non-trivial test-retest variability and can move by years on noise alone.
- Peter de Keizer himself publicly discouraged this and similar self-experimentation, stating that mouse data does not translate to humans and that medium-term and long-term effects in the human body are unknown.
A single n=1 self-experiment with no analytical verification, no control, no blinding, and confounded supplementation is not data. The longevity community itself has been clear about that. Where consumer marketing cites Darren Moore as proof of human efficacy, the reader should treat that as a flag that the marketing is overstating what is known.
2. Vendor and clinic marketing claims that imply human safety based on the mouse data plus anecdotes. These are not evidence; they are claims dressed in the prestige of the journal name “Cell.”
Published human harm reports
A dedicated search of PubMed, Google Scholar, and the published case-report literature found no peer-reviewed case reports of hospitalization, severe inflammation, cytokine release, sepsis, or anaphylaxis specifically attributable to FOXO4-DRI as of the verification date. Community and forum reports of significant adverse events do exist (injection-site reactions ranging from mild burning to severe local inflammation, flu-like syndromes, fatigue, gastrointestinal symptoms, and isolated forum claims of more severe reactions). None of those reports has been formally published.
The absence of published case reports does NOT mean the peptide is safe. It more likely reflects (a) the small denominator of human users, (b) the complete absence of structured pharmacovigilance for research-chemical use, and (c) the practical reality that a biohacker who lands in an ER after self-injecting a research peptide is unlikely to have that incident documented in the peer-reviewed literature.
Dosing: Research Only, All Extrapolation
The honest leading statement: there is no established human dose for FOXO4-DRI. Every protocol described below is biohacker extrapolation from a single mouse study. There are no human pharmacokinetic data, no human dose-response data, and no human safety margin to anchor any recommendation. This section is descriptive of what is observed in community and clinic write-ups; it is not endorsement.
What the mouse paper actually used
Baar et al. (2017) used 5 mg/kg intraperitoneally, every other day for 3 doses per cycle, with cycles repeated at intervals of weeks or longer.
Mouse-to-human allometric scaling (using the Km factor of 12.3 for mouse and 37 for human) would translate that to a human-equivalent dose of approximately 0.4 mg/kg per administration, or roughly 28 mg per dose for a 70 kg adult, every other day for three doses. That is substantially higher than what most biohacker protocols actually use. Allometric scaling is a crude guide. It does not account for differences in target engagement, distribution, plasma protein binding, or clearance between species, and it is not a substitute for an actual human dose-finding study.
What biohacker protocols look like in the wild
These descriptions are reported as a matter of factual observation of what is published in community write-ups and clinic protocols. They are not endorsements. Reading them is not the same as having any reason to believe they are safe or effective in humans.
- Conservative (“low-dose”) protocol: 1 mg subcutaneous, once daily in the morning, 5 days on / 2 days off, two-week cycle. Repeated two to three times per year with three to six months between cycles.
- Mid-range “Baar-inspired” protocol: 2 to 3 mg subcutaneous (or, occasionally, intravenous) every other day for three doses, completing one cycle in five to six days. Cycle repeated every two to six months.
- High-dose / “aggressive” protocols: 10 to 25 mg per injection, three injections per cycle (total ~30 to 75 mg per cycle). This is the upper end seen in some clinic and forum write-ups and represents a 5- to 25-fold multiple over the conservative low-dose protocol. There is no human evidence supporting either the safety or the necessity of this dose range.
- Routes: Subcutaneous is most common in community use; intravenous is reported in some clinic settings; intraperitoneal (the route in the mouse study) is not used in human protocols.
- Cycling: The universal pattern is short, infrequent cycles (days, not weeks of daily dosing) with long off-periods (months). The community rationale is twofold: (1) the mouse mechanism is framed as a “clearance event,” not chronic modulation; (2) the unknown safety profile argues against chronic exposure.
Key dosing uncertainties to communicate honestly
- The mouse paper used intraperitoneal dosing; biohackers use subcutaneous. The bioavailability difference between IP and SC for this peptide is unknown.
- DRI peptides resist most mammalian proteases, so the pharmacokinetic profile differs from L-peptides. What proportion of an injected dose reaches target cells in humans, and over what time course, is unknown.
- The CPP poly-arginine tail enables intracellular entry across many cell types, not just senescent cells. Selectivity comes downstream from the FOXO4-p53 dependency, not from delivery. Off-target intracellular exposure is intrinsic to the molecule’s design.
- The ~10:1 selectivity ratio that de Keizer cites is from cell culture. In vivo, the effective selectivity at any given systemic dose is unknown.
Reconstitution and Handling
- Typical vial sizes: 5 mg and 10 mg are most common from research-peptide suppliers. Some vendors stock 2 mg or 20 mg.
- Diluent: Bacteriostatic water (0.9% benzyl alcohol) is standard for subcutaneous routes. Sterile water for injection is used by some clinics for intravenous administration.
- Typical reconstitution ratio: 2 to 3 mL bacteriostatic water added to a 10 mg vial yields a working concentration of 5 mg/mL or 3.33 mg/mL respectively. For a 1 mg dose, with 2 mL reconstitution into a 10 mg vial, that’s 20 units on a U-100 insulin syringe (0.2 mL of solution).
- Storage of lyophilized material: Stable at -20C long-term. Refrigerated (2 to 8C) is acceptable for shorter periods. Some vendor certificates note stability at room temperature for shipping durations, but extended room-temperature storage is not recommended.
- Storage of reconstituted material: Refrigerated at 2 to 8C, use within 14 to 28 days. Some protocols freeze reconstituted aliquots at -20C to extend shelf life, but freeze-thaw cycling on large peptides can drive aggregation.
- Sterility: Because the peptide is expensive and dosed infrequently, sterile technique is essential. Single-use insulin syringes only; alcohol-swab the vial septum; do not pre-load and store syringes.
- Stability advantage from the DRI design: Because the peptide is built from D-amino acids, it resists most mammalian proteases. That improves stability in solution and likely in vivo half-life relative to an L-amino-acid version, but it does not make the molecule indefinitely stable against oxidation, aggregation, or surface adsorption losses on plastic and glass.
For dose calculation given a chosen vial size, reconstitution volume, and target dose, see the reconstitution calculator on this site.
Safety: Animal Data Does Not Equal Human Data
What was reported in mice
Baar et al. (2017) described FOXO4-DRI as “generally well tolerated” in mice at the 5 mg/kg IP × 3 doses per cycle regimen. No major hematologic toxicity was reported. No acute mortality was attributed to drug at the studied doses.
Those data are from short follow-up periods (weeks to roughly ten months) in inbred laboratory mice held under controlled conditions. The relevance of “well tolerated in C57BL/6 mice over a few months” to “safe in heterogeneous adult humans across years” is not direct.
What we do not have
- No published human safety data of any kind. Not Phase 0, not Phase 1, not Phase 2.
- No published large animal safety data.
- No formal pharmacovigilance dataset on research-peptide use.
- No structured monitoring of vendor product quality in the research-chemical supply chain. Material quality varies between vendors; some publish HPLC and mass-spec certificates, many do not, and even published certificates cannot be independently verified by the end user without sending material to a third-party lab.
Theoretical safety concerns worth surfacing
These are the concerns that follow directly from the peptide’s mechanism and design. None has been formally studied in humans.
1. Off-target p53 induction. p53 is the “guardian of the genome.” Acute systemic p53 activation has been linked, in animal models of cancer therapeutics, to lymphopenia, thrombocytopenia, gastrointestinal mucosal injury, and bone marrow stress. The FOXO4-DRI selectivity argument depends on senescent-cell dependence on FOXO4-mediated p53 sequestration. In non-senescent cells the peptide presumably has limited effect, but at high systemic doses the assumption may not fully hold.
2. Loss of senescent cells with beneficial roles. Senescent cells contribute to wound healing, embryonic and developmental patterning, tumor suppression, and placental development. Systemic senolytic exposure in healthy adults is biologically novel territory. The long-term cost of chronic or repeated cycle clearance is unknown.
3. Cancer surveillance. p53 modulation is a double-edged sword in cancer biology. Inducing p53-mediated apoptosis in cells with borderline p53 function could in principle affect the balance between clearance of pre-malignant cells and disruption of normal cell-cycle checkpoints. This is the theoretical concern that is hardest to test in a self-experimentation context, because the relevant outcomes appear on a timescale of years.
4. Immunogenicity. A 5.4 kDa synthetic D-peptide with a poly-arginine cargo tag is structurally novel to the immune system. D-peptides are generally less immunogenic than L-peptides (they are not efficiently processed by MHC machinery), but “less” is not “non-immunogenic.” Repeat-dose immune responses in humans have not been characterized.
5. Acute cytokine release and SASP burst. When senescent cells are killed, their accumulated SASP cargo is released into the local tissue and circulation. In a chemotherapy patient with a high senescent-cell burden, this could plausibly drive an acute inflammatory response. The biohacker community describes “flu-like symptoms” after dosing; whether that is SASP burst, an immune response to the peptide itself, contamination of the product, or coincidence is unknown.
6. Injection-site reactions. Reported in community use: burning, erythema, induration, occasional sterile abscess. These may reflect the peptide, the formulation, or vendor material quality.
7. Product purity. A non-trivial fraction of harms attributed to research peptides in the wild are driven not by the parent molecule but by impurities: residual synthesis reagents, endotoxin from non-pharmaceutical-grade manufacturing, truncated peptide species, microbial contamination. This applies broadly to research peptides and to FOXO4-DRI specifically. Because the peptide is expensive and the user population small, vendor turnover is high and quality consistency across lots and across vendors is not guaranteed.
A defensible safety summary
In animal studies, FOXO4-DRI was reported as well-tolerated at the doses tested. There are no controlled human safety data. Reports of adverse effects in self-experimenters exist but are anecdotal and unsystematically collected. The peptide’s intended mechanism, inducing apoptosis in senescent cells via p53, is biologically powerful, and the long-term consequences of repeated senolytic exposure in humans are unknown.
Drug Interactions
There is no published drug-drug interaction data for FOXO4-DRI in humans. Everything in this section is theoretical and mechanism-based.
Theoretical interactions worth flagging
- Other senolytics. Dasatinib + quercetin, fisetin, navitoclax (ABT-263), and UBX-series small molecules all act through different molecular mechanisms but converge on the same outcome: senescent-cell apoptosis. Stacking FOXO4-DRI with any of them would be expected to amplify both the desired effect and any off-target toxicity, including SASP-burst inflammation, on-target tissue stress, and any cumulative effect on cells with marginal p53 function. There is no published evidence on whether stacked senolytic exposure is additive, synergistic, or supra-additively toxic in humans.
- Other p53 modulators. Nutlins, MDM2 inhibitors (idasanutlin, navtemadlin), and certain chemotherapeutics modulate the p53 axis through different mechanisms. Combined exposure is biologically plausible to amplify p53 effects.
- Chemotherapy. The original Baar et al. study used FOXO4-DRI to rescue doxorubicin chemotoxicity, so the on-mechanism inference is that FOXO4-DRI might be useful for chemo-induced senescence. Using it concurrently with active chemotherapy in humans has no safety data and is medically inappropriate without oncologist supervision.
- Immunosuppressants (rapamycin, tacrolimus, cyclosporine). Stacking with mTOR inhibitors (e.g., rapamycin) is a popular biohacker combination on theoretical “longevity synergy” grounds. There is no human safety data for this combination.
- NAD+ precursors (NMN, NR), spermidine, metformin. No known pharmacokinetic interaction. Combination is biologically plausible to interact at the cellular metabolism level but has no published evidence either direction.
- Anticoagulants. Theoretical: any acute inflammatory response after dosing could affect coagulation parameters transiently. Not characterized.
The absence of published interaction data does NOT mean the molecule is interaction-free. It means the question has never been formally studied.
For broader peptide interaction context, see our peptide drug interaction overview.
Regulatory Status (2026)
United States. FOXO4-DRI is NOT FDA-approved for any indication. It is NOT a Generally Recognized as Safe (GRAS) substance. It is NOT on the FDA Section 503A bulks list, and it does NOT appear on the FDA Pharmacy Compounding Advisory Committee’s July 23-24, 2026 review agenda. It is sold in the US exclusively as a research chemical for in vitro use, not for human consumption.
The 2026 peptide regulatory framework. Following the FDA’s April 15, 2026 action that removed twelve previously-restricted peptides from Category 2 (the “may pose significant safety risks” list), and the May 1, 2026 announcement of 503B outsourcing-facility exclusions for compounded GLP-1s, the broader research-peptide regulatory environment has tightened around compounding pathways. FOXO4-DRI’s status is unchanged by either action: it was never on the 503A bulks list, and the April 2026 action did not touch it. The July 2026 PCAC meeting will review seven research peptides (BPC-157, TB-500, Epitalon, Semax, Emideltide, and two others) for potential 503A listing. FOXO4-DRI is not on that agenda. Given the complete absence of human clinical data, it would face an exceptionally steep regulatory path even if it were ever submitted.
Cleara Biotech (Utrecht, NL) holds the molecule’s intellectual property lineage and continues development of next-generation candidates. Their current lead programs are not FOXO4-DRI itself but optimized successor molecules, reportedly with higher selectivity targets (~100:1 versus FOXO4-DRI’s ~10:1). As of the most recent public update verifiable at the time of writing, no FDA IND has been publicly disclosed for either FOXO4-DRI or its successors.
Outside the US. Status varies by jurisdiction. In most countries, FOXO4-DRI is unscheduled but unapproved for human use; importation rules vary widely. In the EU, Cleara Biotech operates as a development-stage biotech in the Netherlands. The molecule itself is not approved for human use in any jurisdiction worldwide.
Compliance framing
FOXO4-DRI is not approved by the FDA or any international regulatory body for human use. It is sold as a research chemical for laboratory use only. Information presented here is educational. Nothing in this guide is medical advice. Users who choose to self-administer research peptides do so at their own risk and outside the protections of regulated medicine.
The Honest Bottom Line
A defensible summary line for FOXO4-DRI, suitable as a takeaway:
FOXO4-DRI is one of the most biologically interesting peptides in the longevity space and one of the least studied in humans. The 2017 Cell paper that launched it is real, careful, and impressive in mice. Every additional claim, that it is safe in humans, that it works in humans, that any specific dose is appropriate, that any specific clinical effect is expected, is extrapolation, not evidence. People who choose to use FOXO4-DRI as a research peptide today are participating in an uncontrolled single-person experiment with a molecule whose human risk-benefit profile is fundamentally unknown. That is not the same as saying it is dangerous, and not the same as saying it is safe. It is saying the question has not been answered.
Of every peptide covered on this site, FOXO4-DRI has the largest gap between consumer hype and published human evidence.
Frequently asked questions
Is there a FOXO4-DRI human clinical trial?
No. As of 2026 there are no FOXO4-DRI human clinical trials registered on ClinicalTrials.gov, and none have been published. All existing evidence comes from cell-culture experiments and mouse studies, not from people.
Who developed FOXO4-DRI?
FOXO4-DRI was developed by Peter de Keizer and colleagues at Erasmus University Medical Center in Rotterdam. The keystone study, Baar et al., was published in the journal Cell in 2017.
What is Cleara Biotech doing with FOXO4-DRI?
Cleara Biotech was founded to commercialize the FOXO4/p53 senolytic approach. Rather than advancing the original FOXO4-DRI peptide, it has optimized two next-generation candidates, CL04177 and CL04183, and named CL04183 its development candidate. In 2024 it raised capital to fund Pre-IND work toward a future clinical trial.
Is FOXO4-DRI FDA approved?
No. FOXO4-DRI is not approved by the FDA for any use and is sold only as a research chemical. There is no approved human indication.
How selective is FOXO4-DRI for senescent cells?
In the 2017 mouse research it showed roughly 11-fold selectivity for senescent cells over healthy cells. That figure comes from preclinical models and has not been confirmed in humans.
Read Next
- Epitalon: Pineal Bioregulator Guide, short bioregulator peptide with a different mechanism (telomerase induction) and a more extensive (though still imperfect) human research base.
- Humanin: Mitochondrial Stress Response Peptide, endogenous mitochondrial-derived peptide implicated in longevity signaling. Mechanism and human evidence base discussed.
- MOTS-c: Mitochondrial-Derived Longevity Peptide, another mitochondrial-derived peptide in the longevity research space, with markedly different mechanism (AMPK / metabolic signaling) and a separate evidence profile.
This guide was last reviewed June 2026. The research-peptide vendor landscape and regulatory environment in this space change month-to-month; verify regulatory and vendor claims against current sources before acting on anything in this article.
Related tools: Compare FOXO4-DRI with similar peptides · See FOXO4-DRI’s goal category
Cycle Lengths
Cycling summary: No established cycling protocol for this peptide in the published literature. Community protocols vary; consult a compounding-focused clinician for a personalized plan.
Cycle timing should be informed by the peptide’s half-life, receptor tachyphylaxis profile (if applicable), and personal response monitored through lab work. Log both on-cycle and off-cycle biomarkers to understand recovery kinetics.
Lab Monitoring
Foxo4 Dri is a research-tier healing peptide with no established peripheral efficacy biomarker. Lab monitoring should be prudent general-health surveillance rather than efficacy tracking. The panels below cover organ systems most relevant during peptide research use.
Baseline (before starting): CBC with differential, comprehensive metabolic panel (CMP) covering LFTs and renal function, fasting lipid panel, hs-CRP for inflammatory baseline, fasting glucose, and HbA1c if metabolic risk factors are present. Age-appropriate cancer screening is prudent given rodent-only data on healing/angiogenic activity for most research peptides in this class.
During use: repeat CMP + CBC every 8-12 weeks. Repeat hs-CRP alongside if using for inflammatory conditions to track the inflammatory read against symptom response. Watch trends in ALT/AST (liver) and eGFR (renal) rather than single readings.
What to flag to a physician: injection-site erythema or nodule formation, unexplained weight changes, new joint or mass symptoms, any lab value trending outside reference range across two consecutive draws.
For the full class-wide monitoring framework and a plain-language comparison of DTC lab services for peptide users, see the Peptide Lab Testing pillar guide.
Storage & Travel
Storage
Lyophilized powder: Lyophilized powder freezer -20°C (-4°F) for long-term storage; stable at room temperature for shipping and short-term handling.
Reconstituted: Refrigerate reconstituted vial at 2-8°C (36-46°F); use within ~28 days per USP <797> peptide stability guidance. Never freeze a reconstituted vial, since freeze-thaw cycles damage peptide bonds and reduce potency.
Travel
Domestic flights: pack reconstituted vials in an insulated cooler with reusable ice packs. The TSA 3-1-1 rule limits liquids to 100 mL per container in carry-on; a 3-5 mL peptide vial passes with room to spare. Keep pharmacy or vendor documentation visible for TSA questions. Lyophilized powder in original sealed vial does not require cooling for short trips.
International travel: Foxo4 Dri is a research peptide in most jurisdictions with varying import restrictions — check the destination country’s rules before travel. Carry a physician’s letter if the peptide was prescribed by a compounding-focused clinician.
Road trips: keep the cooler in the cabin, not the trunk, during summer. Hotel mini-fridges vary in temperature stability; an insulated bag inside the mini-fridge adds a buffer.
Emergency out-of-fridge: reconstituted Foxo4 Dri at room temperature under 24 hours is generally still viable per USP stability guidance. Longer excursions or temperatures above 30°C compromise potency; discard and reconstitute a fresh vial.






